Jubilant Life Sciences, an integrated pharmaceutical industry player and the largest custom research and manufacturing services company in India, has repaid $202 million on account of outstanding Foreign Currency Convertible Bonds (FCCBs) including yield-to-maturity (YTM) of $60 million. Following the repayment, no more FCCBs are outstanding in the books.
The company has repaid all the outstanding FCCBs on time, as per schedule, in line with the terms and conditions of the FCCB instruments, showing its commitment to meet its obligation on time and demonstrating its financial strength.
Jubilant Life Sciences is an integrated pharma and life sciences company offering Life Sciences products and services to the global life sciences industry. It is the largest custom research and manufacturing services company and a leading integrated drug discovery and development solutions company out of India.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1665.25 |
| Dr. Reddys Lab | 1220.75 |
| Cipla | 1232.90 |
| Zydus Lifesciences | 928.85 |
| Lupin | 2311.75 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: